Arbutus Biopharma Corp  

(Public, NASDAQ:ABUS)   Watch this stock  
Find more results for Frank G. Cousins, Jr
-0.14 (-2.24%)
Oct 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.01 - 6.41
52 week 5.60 - 26.73
Open 6.25
Vol / Avg. 225,114.00/480,842.00
Mkt cap 340.10M
P/E     -
Div/yield     -
EPS -1.34
Shares 54.33M
Beta 0.92
Inst. own 72%
Nov 5, 2015
Q3 2015 Arbutus Biopharma Corp Earnings Release - Tentative - 4:00PM EST - Add to calendar
Sep 10, 2015
Arbutus Biopharma Corp at Robert W Baird and Co Health Care Conference
Aug 11, 2015
Arbutus Biopharma Corp at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Arbutus Biopharma Corp at Jefferies Hepatitis B Summit
Aug 5, 2015
Q2 2015 Tekmira Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -432.73% -259.73%
Operating margin -419.19% -223.59%
EBITD margin - -216.97%
Return on average assets -7.65% -40.90%
Return on average equity -10.10% -52.76%
Employees 85 -
CDP Score - -


100-8900 Glenlyon Parkway
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Age: 29
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Patrick Higgins Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 58
Bio & Compensation  - Reuters
Adam D. Cutler Senior Vice President - Corporate Affairs
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Michael J. Sofia Ph.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Bruce Dorsey Vice President - Chemistry
Bio & Compensation  - Reuters
Rene Cornelis Rijnbrand Vice President - Biology
Bio & Compensation  - Reuters